anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Composite prosthetic patches with covalently bound particles for controlled drug release, and methods of making and using thereof, have been developed. The particles may encapsulate one or more therapeutic, prophylactic or diagnostic agent(s). Generally, the prosthetic patches are decellularized extracellular matrix such as bovine or porcine pericardium or synthetic polymeric materials. The size of the particles ranges from between 1 nm and 1000 μm, preferably from between 10 nm and 500 nm. In some embodiments, the agent is a therapeutic agent for treatment of neointimal hyperplasia. In other embodiments, the agent is a therapeutic agent for suppressing or resolving inflammation. In yet other embodiments, the agent is a therapeutic for mitigating scarring.
PURPOSE:To obtain an impression material capable of preventing contagion of infectious diseases from a female mold of impression mold, by previously adding a specific amount of a germicide to powder of impression material of alginic acid. CONSTITUTION:0.01-7pts.wt., preferably 0.5-5pts.wt. germicide based on 100pts. wt. cured material of impression material (immediately after blending 16pts.wt. impression material powder with 40pts.wt. water and curing) is added to powder of impression material of alginic acid. Glutaraldehyde or gluconic acid chlorhexidine is used as the germicide, sealed in microcapsules, included in cyclodextrin and added to powder of impression material of alginic acid.
Many drugs, including most drugs effective in the treatment of major depressive disorder (paroxetine, other SSRIs and many tricyclics), are metabolized by the cytochrome P450 isozyme CYP2D6. Like other agents that are metabolized by CYP2D6, paroxetine may significantly inhibit the activity of this isozyme. In most patients (> 90%), this CYP2D6 isozyme is saturated early during dosing with paroxetine tablets. In 1 study, daily dosing of paroxetine tablets (20 mg once daily) under steady-state conditions increased single dose desipramine (100 mg) Cmax, AUC, and T ½ by an average of approximately 2-, 5-, and 3- fold, respectively. Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated. In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold. The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state. In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours. This resulted in increases in steady state atomoxetine AUC values that were 6- to 8-fold greater and in atomoxetine Cmax values that were 3- to 4-fold greater than when atomoxetine was given alone. Dosage adjustment of atomoxetine may be necessary and it is recommended that atomoxetine be initiated at a reduced dose when it is given with paroxetine.

Concomitant use of paroxetine tablets with other drugs metabolized by cytochrome CYP2D6 has not been formally studied but may require lower doses than usually prescribed for either paroxetine tablets or the other drug. 

Therefore, coadministration of paroxetine tablets with other drugs that are metabolized by this isozyme, including certain drugs effective in the treatment of major depressive disorder (e.g., nortriptyline, amitriptyline, imipramine, desipramine, and fluoxetine), phenothiazines, risperidone, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.

However, due to the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, paroxetine and thioridazine should not be coadministered (see CONTRAINDICATIONS and WARNINGS).

Tamoxifen is a pro-drug requiring metabolic activation by CYP2D6. Inhibition of CYP2D6 by paroxetine may lead to reduced plasma concentrations of an active metabolite (endoxifen) and hence reduced efficacy of tamoxifen (see PRECAUTIONS).

At steady state, when the CYP2D6 pathway is essentially saturated, paroxetine clearance is governed by alternative P450 isozymes that, unlike CYP2D6, show no evidence of saturation (see PRECAUTIONS – Tricyclic Antidepressants [TCAs]).
The invention discloses an application of molybdenum-based polyoxometalate clusters in treating inflammatory diseases. Said inflammatory disease is associated with elevated ROS levels. Experiments show that the molybdenum-based polyoxometalate cluster achieves the purpose of preventing or treating inflammatory diseases by reducing the ROS level in tissues. Therefore, the molybdenum-based polyoxometallate cluster can be used for preparing the medicine for treating the inflammatory diseases, the application of the molybdenum-based polyoxometallate cluster is widened, the new medicine for treating the inflammatory diseases is developed, an experimental basis is provided for the molybdenum-based polyoxometallate cluster to treat the clinical inflammatory diseases, and the application prospect is good. The invention also provides a medicament for treating inflammatory diseases. The medicine for treating inflammatory diseases can effectively treat inflammatory diseases.
<P>PROBLEM TO BE SOLVED: To provide an accounting device for suspending an accounting processing in a case where a patient does not come to take medicines though the medicines are prepared based on a prescription, concerning the accounting processing in the prescription counter of a dispensing pharmacy or a hospital.  <P>SOLUTION: The device manages charging the patient and receiving money which occur by dispensing based on the prescription. The device includes an accounting file for registering accounting data of one record in response to one prescription. A dispensing date, and a processing flag indicting whether the accounting processing state is suspended or not are stored in the record. The device also includes a processing means for setting the suspension of the processing flag of the accounting data in response to a user's indication concerning the patient who does not pay an account though the prescription is completed, and registering the flag in an accounting file together with the dispensing date.  <P>COPYRIGHT: (C)2004,JPO
The pharmacodynamics in subjects with hypoparathyroidism after single subcutaneous administration of 50 and 100 mcg dose of NATPARA in the thigh were evaluated.

Treatment with NATPARA increases serum calcium levels (Figure 2). The increase in serum calcium levels in hypoparathyroidism subjects occurs in a dose-related manner. Mean peak serum calcium levels are reached between 10 and 12 hours following a single subcutaneous injection and the increase in serum calcium above baseline is sustained for more than 24 hours after administration. The maximum mean increases of serum calcium, which occurred at 12 hours, were approximately 0.5 mg/dL and 0.7 mg/dL from baseline with the 50 mcg and 100 mcg doses, respectively. The mean calcium intake for the 50 and 100 mcg doses was 1700 mg [see Clinical Pharmacology (12.3)].
1. Valaciclovir hydrochloride in essentially anhydrous crystalline form including substantially the following d spacing pattern (in Angstroms): 10.20 +- 0.08, 8.10 +- 0.06, 7.27 +- 0.06, 6.08 +- 0.05, 5.83 +- 0.03, 5.37 +- 0.02, 5.23 +- 0.02, 4.89 +- 0.02, 4.42 +- 0.02, 4.06 +- 0.02, 3.71 and 0.02, 3.39 +- 0.02, 3.32 +- 0.02, 2.91 +- 0.02, 2.77 +- 0.02. 2. Crystalline valaciclovir hydrochloride as claimed in Claim 1 having a water of hydration content of not more than 3% w/w. 3. Crystalline valaciclovir hydrochloride as claimed in Claim 2 having a water of hydration content of not more than 2% w/w. 4. Crystalline valaciclovir hydrochloride as claimed in Claim 3 having a water of hydration content of not more than 1% w/w. 5. Crystalline valaciclovir hydrochloride having as claimed in any one the preceding Claims substantially the same X-ray diffraction pattern as shown in Figures 1 to 3. 6. Use of crystalline valaciclovir hydrochloride as a medicament for use in medical therapy. 7. A process for the treatment of herpes viral infection in a human which comprises administering to the human host, an effective anti-herpes viral amount of crystalline valaciclovir hydrochioride as claimed in any one of Claims 1 to 5. 8. A process for the production of valaciclovir hydrochloride in anhydrous crystalline form including substantially the d spacings as defined in Claim 1, said process comprising treating valaciclovir hydrochloride with an amount of 15% to 40% w/w lower alcohol having 1 to 4 carbon atoms or a lower ketone containing from 3 to 6 carbon atoms serving to convert an amount of said valaciclovir hydrochloride into said anhydrous crystalline form; and then isolating said anhydrous crystalline form. 9. A process as claimed in Claim 8, wherein before treating valaciclovir hydrochloride with alcohol or ketone and further said process comprising the steps of forming valaciclovir in solution either in free base or salt form, converting said free base valaciclovir or salt thereof to valaciclovir hydrochioride, isolating valaciclovir hydrochioride from the solution and optionally removing unbound solvent leaving the valaciclovir hydrochioride in substantially dry form. 10. A process as claimed in Claim 9 wherein valaciclovir hydrochloride is treated with ethanol or a solvent composed substantially of ethanol. 11. A process as claimed in Claim 10 wherein ethanol or a solvent composed substantially of ethanol and is added in a range of about 17% by weight to about 40% by weight of substantially dry valaciclovir hydrochloride.
the author presented a review on the updates of dental cements, focusing on the composition, properties, advantages, limitations, and indications of the various cements available. Nowadays, dental restorations are made from various biomaterials, and depending on each clinical case, an appropriate luting material will be selected. There is no luting material that can be universally used. Therefore, it is important to distinguish the physical, mechanical, and biological properties of luting materials in order to identify the best options for each case. Nowadays, the most commonly used dental cements are glass-ionomer and resin cement. The type, shade, thickness of resin cement and the shade of the ceramic, all together, have a tangible influence on the final restoration color. Surface treatments of the restoration increase the micro tensile bond strength. Hence, the proper surface treatment protocol of both the substrate and restoration surfaces is needed before cementation. Additionally, the manufacturer's instructions for the thin cement-layer thickness are important for the long-term success of the restoration.

the author conducted a study to evaluate the performance of two different adhesive resin cement systems in the cementation of inlay/onlay restorations produced from resin nanoceramic blocks using the CAD/CAM system. The methodology was total of 70 inlay/onlay restorations made from Cerasmart (GC, Tokyo, Japan) resin nanoceramic blocks using CEREC Omnicam (Sirona Dental, Bensheim, Germany) were placed in 53 patients. The restorations were cemented with RelyX U200 Automix (3M ESPE, Seefeld, Germany) self-adhesive resin cement (RXU) after selective enamel etching or with G-CEM LinkForce (GC, Tokyo, Japan) adhesive resin cement (GCL) in combination with a universal adhesive (G-Premio Bond) in selective etch mode. At baseline and after 6, 12, and 18 months, restorations were examined by two calibrated clinicians according to modified USPHS criteria. . he concluded that the two resin cement systems showed acceptable clinical performance for the cementation of resin nanoceramic CEREC Omnicam inlay

the author conducted a study to evaluate the retention strength of zirconia crowns luted with two types of resin cement under environmental pressure changes.Thirty zirconia crowns were fabricated by using computer-aided design/computer-aided manufacturing (CAD/CAM) system and were cemented by Panavia F2.0 (PAN), hand-mixed RelyX Unicem (UNH), or auto-mix RelyX Unicem Aplicap (UNA) cements on the corresponding extracted human molars. The samples were randomly divided into three groups according to the cement type. After 3000 thermal cycles, the cemented crowns were subjected to 24 pressure cycles (0 to 5 atmospheres). The retention force (N) of the specimens was measured in a universal testing machine. To normalize the retentive force, the recorded force was divided by the surface area of each tooth for measuring the retentive strength (MPa). he concluded that. The adhesive failure mode was predominant in all the groups.
Asthma is a chronic respiratory disease that affects 7% or 14 million adults in the United States. It is one of the four most common chronic disorders in adults, costing an estimated 7.9 billion dollars in medical care and 5.3 billion dollars in lost work or school. Approximately 40% of asthmatics report using some form of complementary and alternative medicine (CAM) approach to help alleviate their asthma symptoms, but there is little evidence for their effectiveness. Breathing and relaxation techniques, including yoga appear most promising. Mindfulness-based stress reduction (MBSR) is a group-based program developed at the University of Massachusetts Medical School (UMMS) that focuses on the cultivation of mindfulness through formal meditation practices and the integration of mindfulness into everyday life as a coping resource to deal with physical symptoms, chronic medical conditions, and difficult emotional situations. MBSR has been shown to be an effective adjunctive intervention in reducing medical symptoms for a broad range of stress-related disorders and chronic diseases, reducing psychological distress anxiety and depression, and improving quality of life. A small preliminary study conducted by our research team found improvements in measures of quality of life, locus of control, stress, and anxiety immediately following the completion of the MBSR program.

The overall goal of the proposed two year exploratory study is to conduct a randomized controlled trial (RCT) to test and optimize recruitment and data collection procedures and to collect preliminary data on the effect of MBSR on behavioral and psychological aspects of asthma and lung function to support justification for a larger clinical trial should the results of this study be promising. Eighty-two adults ages 21 and older with a physician-documented diagnosis of asthma classified as either mild or moderate documented will be recruited for seventy participants at final follow-up. Participants will be randomly assigned to one of two conditions stratified by asthma severity: (1) MBSR, or (2) Healthy Living Course (HLC) attention control condition. Participant assessments will occur at study entry (baseline) and at 10-week, 6- and 12-month follow-up. The primary aim of the project is to evaluate the efficacy of the MBSR program in improving quality of life and lung function as assessed by change from baseline to two-week average morning peak expiratory flow (PEF) compared to HLC participants. Secondary aims are to evaluate the effect of the MBSR program on reducing asthma rescue medication use, frequency of asthma exacerbations (prednisone therapy), asthma symptoms, healthcare utilization, number of days of work or school missed, peak expiratory flow (PEF) variation, and psychological distress, and in improving asthma control, asthma-related internal locus of control, and lung function as assessed by spirometry (FEV1).
The invention relates to a traditional Chinese medicine composition for treating new coronavirus and a preparation method thereof, belonging to the field of medical treatment. The traditional Chinese medicine composition takes natural traditional Chinese medicines as raw materials, and comprises the following components in parts by weight: 2-5 parts of caulis piperis longifoliae, 2-5 parts of roselle calyx, 2-5 parts of fructus forsythiae, 2-5 parts of common camptotheca fruit, 1-2 parts of asiatic moonseed rhizome, 2-5 parts of dandelion, 2-5 parts of rheum officinale, 2-5 parts of isatis root, 2-5 parts of astragalus membranaceus, 2-5 parts of moutan bark, 1-3 parts of gypsum and 2-5 parts of honey-fried licorice root. The preparation method of the invention mainly comprises two methods. The components can be pulverized into superfine powder and encapsulated to prepare a capsule preparation, or pulverized into coarse powder and decocted to prepare a decoction. But are not limited to these two methods of preparation. The invention theoretically has treatment effect on various virus infections.
An increasing number of studies have indicated the crucial involvement of long non-coding RNAs (lncRNAs) in the onset and progression of malignancies. However, a complete understanding of the molecular mechanism underlying the effect of abnormally expressed lncRNAs on breast cancer (BC) remains elusive. This study aimed to elucidate the influence of the lncRNA small nucleolar RNA host gene 1 (SNHG1) on BC progression and its underlying mechanism. Our findings revealed a conspicuous up-regulation of SNHG1 in both BC tissues and cells. The downregulation of SNHG1 was observed to inhibit BC cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) processes, while simultaneously promoting apoptosis. Furthermore, dual-luciferase reporter gene and RNA pull-down assays established that SNHG1 targeted miR-641 expression, while miR-641 targeted RRS1. Rescue studies demonstrated that in vitro SNHG1 silencing could be reversed by the miR-641 inhibitor, as well as by RRS1 upregulation. Moreover, in vivo downregulation of SNHG1 was found to inhibit BC growth. Through the inhibition of the miR-641 level, SNHG1 elevated the level of the downstream target RRS1, thereby fostering BC growth, migration, and invasion while inhibiting apoptosis. These findings suggest that SNHG1 may represent a potential therapeutic target for BC treatment.
AIM: The preoperative diagnostic method for superficial esophageal squamous cell carcinoma (SESCC) invasion depth based on the Japan Esophageal Society (JES) classification has been promoted. However, there have been a few investigations into its diagnostic performance in clinical settings. Therefore, we aimed to elucidate the actual diagnostic performance of the JES classification using a single-center retrospective study design.
METHODS: We retrospectively analyzed the clinical data of 315 newly diagnosed SESCC patients who underwent narrow-band imaging magnifying endoscopy (NBI-ME) examination and received endoscopic submucosal dissection (ESD) or esophagectomy in our center during the past 5 years. To evaluate the diagnostic performance of JES classification in assessing the depth of invasion of SESCC, clinical data of these patients were collected, and the concordance between NBI-ME findings and postoperative pathology reports was analyzed.
RESULTS: This study included a total of 338 lesions. The diagnostic accuracy of vascular morphology was 76.0%. The sensitivity (87.0%) and positive predictive value (PPV, 85.4%) of B1 vessels were high, but the specificity (42.0%) and negative predictive value (NPV, 45.3%) were low. The specificity (86.9% and 98.8%) and NPVs (87.5% and 96.8%) of B2 and B3 vessels were high, but the sensitivity (36.4% and 21.4%) and PPVs (35.1% and 42.9%) ware low. Furthermore, only a few lesions (n = 57) described avascular area, but the overall diagnostic accuracy was not ideal (21.1%). However, if lesions invading the superficial submucosa or shallower were included in the category of "suitable for ESD", the overall accuracy of the JES classification was found to be 95.6%.
CONCLUSIONS: In actual clinical settings, the overall accuracy of the JES classification system decreases, but the diagnostic performance of each subtype retains its original characteristics. Additionally, this classification is appropriate for determining whether type 0-II SESCC lesions are suitable for ESD.
Schizophrenia is a disabling mental disorder that affects approximately 1% of the population worldwide. People with schizophrenia frequently experience hallucinations, delusions, disordered thinking, movement disorders, emotional numbness, social withdrawal, and cognitive deficits. These symptoms can hinder a person's ability to perform everyday functions, such as hold a job and maintain normal social relationships. When combined with medication, family-oriented therapy interventions have been beneficial for people with schizophrenia. There are few programs, however, that are tailored to the needs of minorities. With the rising number of minority populations in the U.S., it is important to develop psychotherapy interventions that are designed specifically for these groups. This study will evaluate the effectiveness of a culturally based family therapy intervention in improving treatment outcome in people with schizophrenia.

Participants in this 12-month, open label study will first attend a 2-hour screening visit, at which information will be gathered regarding coping styles, spirituality, and expressed emotion. Participants will then be randomly assigned to receive either culturally based therapy or treatment as usual. Although the culturally based therapy will be tailored to the needs and values of Hispanics, people who are not Hispanic will not be excluded. The culturally based therapy will entail 15 weekly therapy sessions, which will focus on family unity, psychoeducation, spirituality, communication skills, and problem-solving. The group receiving treatment as usual will attend 3 weekly psychoeducation sessions that will focus on informing participants about schizophrenia. Outcomes for both groups will be assessed upon completion of treatment and at follow-up visits at Months 6 and 12.
This invention relates to egg white copper (II) complexes exhibits therapeutic effects. Pure egg white is mixed with sodium chloride and copper salt in warm water at a suitable PH value. A paste of copper peptide complex could be achieved. After purification of such a paste with water, it could be mixed with preservative and some retinoic acid and L-ascorbic acid. On medical use a proper percentage could be suspended in vehicle such \as gelatin 6% solution to be used for treatment of gastric and duodenal ulcers. For skin injuries diseases and burns or/and for grey hair, Dandruff and hair loss. A mixture with softening media such as paraffin with little amounts of aloavera oil and fragrant could be tobically used more than one time a day.